CG Oncology (CGON) Operating Income (2023 - 2026)
CG Oncology (CGON) posted Operating Income of -$66.4 million for Q1 2026, down 36.32% on a QoQ basis from -$48.7 million in Q4 2025, and down 57.3% year-over-year from -$155.5 million in Q1 2025.
CG Oncology (CGON) Operating Income (2023 - 2026) Analysis & Trends
CG Oncology's Operating Income history runs 4 years deep, the most recent figure standing at -$66.4 million for Q1 2026.
- Quarterly Operating Income fell 57.3% year-over-year to -$66.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$215.0 million (down 59.94% YoY) and the FY2025 annual result came in at -$190.8 million, down 66.37% from the prior year.
- Operating Income was -$66.4 million for Q1 2026 at CG Oncology, down from -$48.7 million in the prior quarter.
- Across five years, Operating Income topped out at -$9.7 million in Q1 2023 and bottomed at -$66.4 million in Q1 2026.
- A 4-year average of -$32.9 million and a median of -$28.3 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2024 — Operating Income slumped 131.14% — and 2025, when it retreated 27.99%.
- CG Oncology's Operating Income stood at -$19.4 million in 2023, then slumped by 96.58% to -$38.0 million in 2024, then fell by 27.99% to -$48.7 million in 2025, then sank by 36.32% to -$66.4 million in 2026.
- Business Quant data shows CGON's Operating Income at -$66.4 million in Q1 2026, -$48.7 million in Q4 2025, and -$51.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | CG Oncology | 6.01 Bn | 6.01 Bn | -1.88 Mn | -66.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -66.39 Mn |
| Dec 31, 2025 | -48.70 Mn |
| Sep 30, 2025 | -51.13 Mn |
| Jun 30, 2025 | -48.74 Mn |
| Mar 31, 2025 | -42.20 Mn |
| Dec 31, 2024 | -38.05 Mn |
| Sep 30, 2024 | -28.30 Mn |
| Jun 30, 2024 | -25.85 Mn |
| Mar 31, 2024 | -22.47 Mn |
| Dec 31, 2023 | -19.36 Mn |
| Sep 30, 2023 | -14.04 Mn |
| Jun 30, 2023 | -12.33 Mn |
| Mar 31, 2023 | -9.72 Mn |